Toutes les études
Actif, mais pas en recrutementPHASE4INTERVENTIONNEL

Combined Active Treatment in Type 2 Diabetes with NASH

This research study is investigating new treatments for a liver condition called Non-alcoholic Steatohepatitis (NASH), which is common in people with type 2 diabetes. Currently, there are no specific medications approved for NASH. This study aims to see if two existing diabetes medicines, empagliflozin and semaglutide, either alone or together, can help improve liver health in these patients. We need volunteers aged 25 to 75 who have type 2 diabetes and NASH, but haven't developed advanced liver scarring (cirrhosis). Participants will receive either one of the medicines, a combination of both, or a placebo (a dummy pill) over 48 weeks. Liver biopsies will be taken at the start and end of the study to check for improvements. Your participation could help find much-needed treatments for this serious liver condition.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE4
Sponsor
German Diabetes Center
Objectif d'inscription
192
Démarrer
26 Mar 2021
Achèvement estimé
01 Déc 2025

De quoi parle cette étude ?

Many people with type 2 diabetes also have a liver condition called Non-alcoholic Fatty Liver Disease (NAFLD). A more serious form of this condition is Non-alcoholic Steatohepatitis, or NASH. If you have type 2 diabetes and NASH, you're at a higher risk of developing more severe liver problems. Sadly, NASH can lead to serious health issues, including greater risk of liver-related death and heart problems.

At the moment, there aren't any specific medications approved for treating NASH in people with type 2 diabetes. This means doctors don't have dedicated ways to help patients with this condition improve their liver health. That's why this study is so important; it's looking for new solutions.

This study will investigate two medicines that are already used for type 2 diabetes: empagliflozin and semaglutide. We want to see if these medicines, used either on their own or together, can help improve the liver changes seen in NASH. By taking part, you could help us find effective treatments that could improve the lives of many people with type 2 diabetes and NASH.

Points clés

  • New study for NASH in people with type 2 diabetes.
  • Testing two existing diabetes medicines (empagliflozin and semaglutide).
  • Aims to find the first specific treatments for NASH.
  • Requires a liver biopsy before and after treatment to check progress.
  • Participation could help improve care for many patients.

Qui peut être éligible ?

To be considered for this study, you would need to:

Be between 25 and 75 years old. Have a diagnosis of type 2 diabetes and a confirmed diagnosis of NASH, but without severe liver scarring (known as cirrhosis). Your diabetes control, measured by something called HbA1c, should be at or below 9.5%.

There are also some reasons why you wouldn't be able to join. These include having other types of liver disease (like Hepatitis B or C), a history of heavy alcohol use, or certain other medical conditions. If you've ever had diabetic ketoacidosis (a serious diabetes complication) or used certain medications that can affect the liver, you also wouldn't be able to take part. Women who are pregnant, breastfeeding, or planning to become pregnant during the study would also not be able to join.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Are you between 25 and 75 years old?
  2. Do you have type 2 diabetes and confirmed NASH?
  3. Is your HbA1c (a diabetes blood test) 9.5% or lower?
  4. Are you able to undergo a liver biopsy?
  5. Are you not pregnant, breastfeeding, or planning to get pregnant soon?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, you'll be assigned to one of three groups by chance, like flipping a coin. You won't know which group you're in, and neither will your doctors (this is called 'double-blind'). You'll either receive: * Empagliflozin tablets combined with injections of semaglutide. * Empagliflozin tablets combined with 'dummy' injections (placebo). * 'Dummy' empagliflozin tablets (placebo) combined with 'dummy' injections (placebo).

The medication will be taken for 48 weeks (about 11 months). To check your liver health, you will need to have a liver biopsy before you start the treatment and another one at the end of the 48-week period. There will also be regular check-ups, blood tests, and assessments throughout the study to monitor your health and how the treatment is working. We cannot tell you the exact number of visits, but typically studies like this involve several clinic visits over the 48-week period. The overall duration you'd be involved in the study would be slightly longer than 48 weeks to allow for initial screening and final follow-up tests.

Risques et avantages potentiels

Potential benefits of participating include gaining access to new treatments before they are widely available and contributing to medical knowledge that could help future patients with NASH and type 2 diabetes. There are potential risks associated with any medical study, including side effects from the study medications (though these are already approved drugs, so common side effects are known) and discomfort or rare complications from procedures like liver biopsies. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Emplacements (26)

  • Medizinische Universität Graz
    Code postal vérifié
    Graz, Autriche
  • Medizinische Universität Innsbruck
    Code postal vérifié
    Innsbruck, Austria
  • Wiener Gesundheitsverbund, Klinik Landstraße
    Code postal vérifié
    Vienne, Autriche
  • Medizinische Universität Wien
    Code postal vérifié
    Vienne, Autriche
  • Wiener Gesundheitsverbund, Klinik Hietzing
    Code postal vérifié
    Vienne, Autriche
  • German Diabetes Center
    Code postal vérifié
    Düsseldorf, Allemagne
  • Herz- und Diabeteszentrum NRW
    Code postal vérifié
    Bad Oeynhausen, Germany
  • Franziskus-Krankenhaus Berlin
    Code postal vérifié
    Berlin, Allemagne
  • Leber- und Studienzentrum Checkpoint
    Code postal vérifié
    Berlin, Allemagne
  • University Clinics Berlin Charité
    Code postal vérifié
    Berlin, Allemagne
  • University Clinics Berlin Charité
    Code postal vérifié
    Berlin, Allemagne
  • University Clinics Bochum
    Code postal vérifié
    Bochum, Germany

Questions fréquentes

What is NASH?

NASH stands for Non-alcoholic Steatohepatitis, which is a serious type of fatty liver disease that can cause inflammation and liver damage.

Qu'est-ce qu'un placebo ?

A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active ingredients. It helps researchers compare the effects of the actual medicine.

Will I know if I'm getting the real medicine?

No, you won't know if you're getting the active medicine or the placebo. This is to make sure the study results are as fair and accurate as possible.

What happens if I decide to leave the study early?

You are free to leave the study at any time, for any reason. Your decision will not affect your regular medical care.

Why do I need a liver biopsy?

A liver biopsy is used to get a small sample of your liver tissue. This is the best way to confirm you have NASH and to see if the treatment has made any improvements to your liver.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.